Biomarkers in Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous disorder developing from multiple aetiologies with overlapping pathophysiological mechanisms. HFpEF diagnosis may be challenging, as neither cardiac imaging nor physical examination are sensitive in this situation. Here, we re...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2022-06-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2021.37 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850110338402353152 |
|---|---|
| author | Antoni Bayes-Genis Germán Cediel Mar Domingo Pau Codina Evelyn Santiago Josep Lupón |
| author_facet | Antoni Bayes-Genis Germán Cediel Mar Domingo Pau Codina Evelyn Santiago Josep Lupón |
| author_sort | Antoni Bayes-Genis |
| collection | DOAJ |
| description | Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous disorder developing from multiple aetiologies with overlapping pathophysiological mechanisms. HFpEF diagnosis may be challenging, as neither cardiac imaging nor physical examination are sensitive in this situation. Here, we review biomarkers of HFpEF, of which the best supported are related to myocardial stretch and injury, including natriuretic peptides and cardiac troponins. An overview of biomarkers of inflammation, extracellular matrix derangements and fibrosis, senescence, vascular dysfunction, anaemia/iron deficiency and obesity is also provided. Finally, novel biomarkers from -omics technologies, including plasma metabolites and circulating microRNAs, are outlined briefly. A cardiac-centred approach to HFpEF diagnosis using natriuretic peptides seems reasonable at present in clinical practice. A holistic approach including biomarkers that provide information on the non-cardiac components of the HFpEF syndrome may enrich our understanding of the disease and may be useful in classifying HFpEF phenotypes or endotypes that may guide patient selection in HFpEF trials. |
| format | Article |
| id | doaj-art-6dbbbc7396fe473cbecb0328f03cfd31 |
| institution | OA Journals |
| issn | 2057-7540 2057-7559 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | Cardiac Failure Review |
| spelling | doaj-art-6dbbbc7396fe473cbecb0328f03cfd312025-08-20T02:37:51ZengRadcliffe Medical MediaCardiac Failure Review2057-75402057-75592022-06-01810.15420/cfr.2021.37Biomarkers in Heart Failure with Preserved Ejection FractionAntoni Bayes-Genis0Germán Cediel1Mar Domingo2Pau Codina3Evelyn Santiago4Josep Lupón5Heart Institute, University Hospital Germans Trias i Pujol, Badalona, Spain; Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain; CIBERCV, Instituto de Salud Carlos III, Madrid, SpainHeart Institute, University Hospital Germans Trias i Pujol, Badalona, Spain; CIBERCV, Instituto de Salud Carlos III, Madrid, SpainHeart Institute, University Hospital Germans Trias i Pujol, Badalona, Spain; CIBERCV, Instituto de Salud Carlos III, Madrid, SpainHeart Institute, University Hospital Germans Trias i Pujol, Badalona, Spain; CIBERCV, Instituto de Salud Carlos III, Madrid, SpainHeart Institute, University Hospital Germans Trias i Pujol, Badalona, Spain; CIBERCV, Instituto de Salud Carlos III, Madrid, SpainHeart Institute, University Hospital Germans Trias i Pujol, Badalona, Spain; CIBERCV, Instituto de Salud Carlos III, Madrid, SpainHeart failure with preserved ejection fraction (HFpEF) is a heterogeneous disorder developing from multiple aetiologies with overlapping pathophysiological mechanisms. HFpEF diagnosis may be challenging, as neither cardiac imaging nor physical examination are sensitive in this situation. Here, we review biomarkers of HFpEF, of which the best supported are related to myocardial stretch and injury, including natriuretic peptides and cardiac troponins. An overview of biomarkers of inflammation, extracellular matrix derangements and fibrosis, senescence, vascular dysfunction, anaemia/iron deficiency and obesity is also provided. Finally, novel biomarkers from -omics technologies, including plasma metabolites and circulating microRNAs, are outlined briefly. A cardiac-centred approach to HFpEF diagnosis using natriuretic peptides seems reasonable at present in clinical practice. A holistic approach including biomarkers that provide information on the non-cardiac components of the HFpEF syndrome may enrich our understanding of the disease and may be useful in classifying HFpEF phenotypes or endotypes that may guide patient selection in HFpEF trials.https://www.cfrjournal.com/articleindex/cfr.2021.37 |
| spellingShingle | Antoni Bayes-Genis Germán Cediel Mar Domingo Pau Codina Evelyn Santiago Josep Lupón Biomarkers in Heart Failure with Preserved Ejection Fraction Cardiac Failure Review |
| title | Biomarkers in Heart Failure with Preserved Ejection Fraction |
| title_full | Biomarkers in Heart Failure with Preserved Ejection Fraction |
| title_fullStr | Biomarkers in Heart Failure with Preserved Ejection Fraction |
| title_full_unstemmed | Biomarkers in Heart Failure with Preserved Ejection Fraction |
| title_short | Biomarkers in Heart Failure with Preserved Ejection Fraction |
| title_sort | biomarkers in heart failure with preserved ejection fraction |
| url | https://www.cfrjournal.com/articleindex/cfr.2021.37 |
| work_keys_str_mv | AT antonibayesgenis biomarkersinheartfailurewithpreservedejectionfraction AT germancediel biomarkersinheartfailurewithpreservedejectionfraction AT mardomingo biomarkersinheartfailurewithpreservedejectionfraction AT paucodina biomarkersinheartfailurewithpreservedejectionfraction AT evelynsantiago biomarkersinheartfailurewithpreservedejectionfraction AT joseplupon biomarkersinheartfailurewithpreservedejectionfraction |